Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Amplia Therapeutics Ltd. reported promising results from its ongoing Phase 2a ACCENT trial, where its drug narmafotinib showed a higher objective response rate and longer patient time on trial compared to historical data in treating advanced pancreatic cancer. The trial has seen nine confirmed partial responses among the initial patients and is advancing ahead of schedule in recruitment. This progress highlights potential efficacy and tolerability of narmafotinib when combined with standard chemotherapy treatments.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
